SOUTH SAN FRANCISCO, Calif. — Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for cancer, announced the appointment of Rob Lauzen as chief financial officer. Lauzen brings extensive financial expertise and deep experience in the life sciences sector, most recently serving as CFO of Prilenia Therapeutics, where he oversaw the company’s capital strategy, finance operations, and investor relations.
“We are thrilled to welcome Rob to the Circle Pharma leadership team,” said David J. Earp, J.D., Ph.D., president and chief executive officer of Circle Pharma. “This is an exciting time for Circle as we advance our lead program, CID-078, through Phase 1 clinical development and continue to expand our pipeline of first-in-class oral macrocycle therapeutics that target cyclins — key drivers of cancer long considered undruggable. Rob’s proven expertise in corporate finance, capital markets, and strategic planning will be instrumental as we build on our momentum and position the company for long-term growth.”
Before joining Prilenia Therapeutics, Lauzen served as vice president of investor relations and head of financial planning and analysis at Dyne Therapeutics. Earlier in his career, he worked in Morgan Stanley’s healthcare investment banking group, advising clients on strategic and financing transactions totaling more than $185 billion in mergers and acquisitions and over $10 billion in equity offerings. Lauzen holds a Bachelor of Arts in engineering sciences from Dartmouth College.
“I’m excited to join Circle Pharma at such a pivotal stage in its evolution,” said Lauzen. “With a strong scientific foundation and a clear focus on cyclins implicated in large populations of cancer patients, Circle is well positioned to deliver transformative new therapies. I look forward to supporting the team’s mission to translate this groundbreaking science into meaningful benefits for patients and value for our stakeholders.”
